

GPOconnect GPO Member

What's New?

Membership

- The Drug Opportunities tab in GPOconnect allows Health Systems Specialty Network (SAN) members to Opt-out of specific drug opportunities. Members of other GPOs will see a message that there are no drug opportunities at this time.

Rebate Payment Summary

- The Grandparent and Parent filters now include the Name, making it easier to select the correct entry without knowing the account number.
- The Payment Period column has been changed to Payment Date to give more accurate information. You can sort the view by Payment Date to make it easier to locate a particular payment. The default sorting is by Payment Number.

Rebate Allocation Report

- Estimated values are now highlighted in purple to make it easier to determine estimates versus actual values.

Grandparent(s) All | Parent(s) All | Child Site Name(s) All

Period Earned All | Product Name(s) All | [Reset All Filters](#)

Highlighted allocation payments are estimates only and based on AB sales data, not manufacturer data.

Address	City	ST	ZIP	HIN	Payment Period	Period Earned	Product Name	Calculated Allocation Payment	Allocat
						Q4 2022		81.04	
						Q4 2022		701.62	
						Q4 2022		2,650.93	

Scorecard

- A checkbox to **Show Portfolio Agreements** has been added to the filters to allow you to see portfolio agreements, including any agreement with a primary drug and other drugs measured under the same agreement.

Expand/Collapse Filters

Member Name: 0600071403 - FL CANCER SPEC & RESEARCH INST LLC

Quarter: Q2 2023 | Manufacturer(s): All | Product(s): All Products | GPO: ION | [Show Scorecard](#)

Show Portfolio Agreements

Contract Type: All | Days Over EOQ to Next Tier: 0.00 to 1,000.1 | [Export](#)

Show Products with Zero Sales
 QTR Achieved

- The **Sold to Details** now shows all contracted drugs for the agreements, including portfolio agreements with multiple contracted drugs under the same agreement.

Parent	Child Name	Item Name	Delivered Quantity	Contract Unit	% of Total Contract Units
		Vabysmo			
		Lucentis			
		Lucentis			
		Vabysmo			
		Vabysmo			

- The Scorecard now shows all drugs in the portfolio, including biosimilars. This information is also available in the Contract Unit Breakdown.

Zirabev (Quarterly)

PFIZER INC / HOSPIRA

ION Rebate Pfizer Biosim Individual Market Share

Member Contribution

QTD	Run Rate	Projected Volume	Market Share	Market Basket

Category: Market Share Method: Volume Volume Type: WAC Measured: Quarterly Unit of Measure: 100.00 MG Measurement Period: 7/1/2022 - 9/30/2022

Tiers	Tier Minimum	Value	Quantity to Tier	Achievements	Other Market Baskets	Value	Market Share %
0				Trending to Achieve	Rituxan		
1				Trending to Achieve	TRUXIMA		
2				Trending to Achieve	Mvasi		
3				Trending to Achieve	Avastin		
					Kanjinti		

Contract Unit Breakdown

Item Name	Description	Delivered Quantity
Zirabev	RUXIENCE 500 MG SDV 50 ML	
Zirabev	ZIRABEV 100 MG SDV 4 ML	
Zirabev	TRAZIMERA 420 MG MDV	
Zirabev	ZIRABEV 400 MG SDV 16 ML	
Zirabev	RUXIENCE 100 MG SDV 10 ML	

Portfolio Products	Value	Market Share %
Ruxience		
TRAZIMERA		
Zirabev		

- The Contract Unit Breakdown has been enhanced by adding a period column that indicates the measurement period in which the units are counted. Also, the table is now in a pivot format with subtotals and the ability to expand/collapse groups.

Period	Product	Descriptor	Delivered Quantity	Contract Unit Quantity	Contract Unit Percentage	Suggested Breakdown for Delta to QTD Goal	WAC
01/01/2023 to 03/31/2023	Lucentis	LUCENTIS 0.3MG PFS	6098.00	6098.00	20.94%		7,134,660.00
		LUCENTIS 0.5MG PFS	23030.00	23030.00	79.06%		44,908,500.00
	Total		29128.00	29128.00	100.00%		52,043,160.00
	Vabysmo	VABYSMO 6 MG SDV	20181.00	60543.00	100.00%		44,196,390.00
	Total		20181.00	60543.00	100.00%		44,196,390.00

- Market Share goals can now be set for a value lower than the current market share on a member's scorecard. This will help members to know the goal to not drop below throughout the quarter.